Ginekol Pol
-
Controlled Clinical Trial
[Efficacy of standardized isoflavones extract (Soyfem) (52-104 mg/24h) in moderate and medium-severe climacteric syndrome].
In recent years, considerable attention has been paid to isoflavones and their proprieties to alleviate the climacteric symptoms. The goal of this study was to evaluate the efficacy of standardized isoflavones extract (Soyfem) in moderate and medium-severe climacteric syndrome. ⋯ Administration of Soyfem in the dosage 52 to 104 mg/24 hours (2 times daily 1 or 2 tablets) is a safe and effective therapy in the postmenopausal women with moderate and medium-severe climacteric syndrome evaluated according to the Kupperman index. Administration of Soyfem is connected with a good compliance and correlated with well-being in the investigated women allowing a long-term administration.
-
Newborns weighing 4000g or heavier, are defined as macrosomic. ⋯ Women over 30, medium height or tall, who gain over 15 kilos during the pregnancy, tend to deliver macrosomic babies. Multiparas who had given birth to the marosomic babies once before, are predisposed to deliver macrosomic neonate in the following pregnancy. On the basis of our studies, we have determined 4kg as a borderline birth weight for increased frequency of parturient canal injuries.